Jim Wil­son and Tachi Ya­ma­da are at it again — launch­ing a 2nd-gen gene ther­a­py com­pa­ny with an ap­petite for risk, glob­al vi­sion and $200M to gam­ble with

When Tachi Ya­ma­da and Jim Wil­son part­nered on launch­ing Pas­sage Bio $PASG, the game plan was to use their con­sid­er­able com­bined sci­en­tif­ic knowhow and glob­al busi­ness con­nec­tions to leap out with new pro­grams for a slate of prospects — ther­a­pies that they could be rel­a­tive­ly sure of get­ting through piv­otal stud­ies and open­ing fields for rare CNS dis­eases. Work­ing with Penn’s Gene Ther­a­py Pro­gram, now close to 400 strong on staff, they have a prod­uct en­gine and clin­i­cal de­vel­op­ment plan to get drugs through to the mar­ket­place.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER